Post-Bariatric Weight Response
Cross-source consensus on Post-Bariatric Weight Response from 1 sources and 5 claims.
1 sources · 5 claims
Risks & contraindications
Comparisons
Other
Other
Highlighted claims
- BARI-STEP defined poor weight loss as less than 20% weight loss at least one year after primary gastric bypass or sleeve gastrectomy. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- The trial included both suboptimal initial weight loss and weight regain after initial loss. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Poor initial weight loss or later regain is clinically important because postsurgical benefits depend strongly on weight loss. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- About one fifth of people who undergo metabolic and bariatric surgery have a suboptimal clinical response. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial
- Revisional surgery has historically been used for inadequate post-bariatric weight outcomes but has important limitations. — Semaglutide versus placebo in individuals with poor weight loss after bariatric surgery: a double-blinded, randomized, placebo-controlled trial